• Skip to primary navigation
  • Skip to main content
  • Skip to footer

Target ALS

A New York based ALS research organization that's leading the fight for a cure.

  • DONATE
  • About Us
    • Our Mission
    • Our Impact
    • Our Team
    • Our Partners
  • For Scientists
    • Research Core Facilities
      • Longitudinal Biofluids Core
      • Human Postmortem Tissue Core
      • Genomic Datasets
      • Animal Models
      • In Vivo Target Validation Core
      • Stem Cell Core
      • Antibody Core
      • Viral Vector Core
    • Funding Opportunities
    • Funded Consortia
    • Annual Meeting
  • ALS Resources
    • The Science, Explained
    • Glossary
    • FAQ
    • Blog
    • Video Library
  • Take Action
    • Contact Us
    • Email Sign Up
    • Donate Now
    • Ways to Give
    • Donate Biofluid Samples
    • Corporate Council

Our Team

DANIEL L. DOCTOROFF

Having lost both his father and uncle to ALS, Daniel L. Doctoroff founded Target ALS in 2013 in collaboration with Bloomberg Philanthropies and financier and philanthropist David Rubenstein to create a new collaborative framework for scientists.

Mr. Doctoroff is currently the Founder and Chief Executive Officer of Sidewalk Labs, an Alphabet company that accelerates the integration of digital technology into urban environments. Prior to forming Sidewalk Labs, he was president and CEO of Bloomberg LP, the leading provider of financial news and information, and before that he was New York City’s longest-serving Deputy Mayor for Economic Development and Rebuilding.

Prior to serving as Deputy Mayor, he was a managing director at Oak Hill Capital Partners. He serves on the boards of the University of Chicago, United States Olympic Committee, Bloomberg Philanthropies, World Resources Institute, and Human Rights First. He is the Founder and Chairman of The Shed, New York’s newest cultural institution. He is the author of Greater Than Ever: New York’s Big Comeback.

“This is a devastating disease, and there’s been little hope for those diagnosed, including my father and uncle. Thanks to promising research of the past few years, we now have the opportunity to radically change the progression of the disease and improve people’s lives.”

– Daniel L. Doctoroff, Founder

Target ALS Team

We have built a team that brings together a unique mix of clinical, scientific, business, and philanthropic expertise.

Kenneth Devaney
Chief Operations Officer
Connect on LinkedIn
Amy Easton, Ph.D.
Senior Director of Scientific Programs
Manish Raisinghani, M.B.B.S., Ph.D.
Chief Executive Officer,
Target ALS
Connect on LinkedIn
Clint Ramnarine
Grants & Database Manager
Connect on LinkedIn
Yuliya Rzad
Chief Grants Officer
Connect on LinkedIn
Burhan Siddiqui
Accounting & Financial Systems Manager
Connect on LinkedIn

Foundation Advisors

Our Foundation Advisors guide the Target ALS administration in ensuring that we are following best-in-class scientific approaches in our work, and they keep us closely connected to the latest developments in the field.

Chris Henderson, Ph.D.
Chief Advisor, Target ALS
SVP, Head of Research, Biogen
Leonard Petrucelli, Ph.D.
Chief Scientific Advisor, Target ALS
Professor of Neuroscience, Mayo Clinic

Board Members

The Target ALS Board of Directors sets overall policy and provides guidance to the Foundation’s executive leadership team. To ensure we craft truly groundbreaking strategies to foster collaboration and accelerate drug discovery and development, we have recruited a renowned, passionate group of pioneering academic leaders, pharmaceutical and biotech executives, patients and their family members, and visionary philanthropists.

Daniel L. Doctoroff
Founder & Board Chair, Target ALS
Founder & CEO, Sidewalk Labs
Alisa Doctoroff
Chair,
Jim Joseph Foundation
John Dunlop, Ph.D.
CSO,
Neumora Therapeutics
Zach Hall, Ph.D.
Chair, Target ALS COI Committee
Former Director, NIH NINDS
Richard Hargreaves, Ph.D.
Corporate Vice President,
Bristol-Myers Squibb
Carole Ho, M.D.
Chief Medical Officer & Head of Development,
Denali Therapeutics
Story Landis, Ph.D.
Former Director, NIH NINDS, Board Liaison, Independent Review Committee
Mike Poole, M.D.
Senior Advisor,
Neumora Therapeutics
Sarah I. Sheikh, BM BCh, MSc, MRCP
Senior Vice President, Neuroscience
Takeda
Stacie Weninger, Ph.D.
President,
F-Prime Biomedical Research Initiative

Independent Review Committee

To avoid Conflicts of Interest (COI), all board and committee members, as well as staff, abide by a comprehensive COI policy and are neither allowed to apply for, nor receive funding from, Target ALS. The committee is chaired by Robert Miller, Ph.D., George Washington University.

Michael Ahlijanian, Ph.D
Chief Scientific Officer,
Pinteon Therapeutics
Manzoor Bhat, Ph.D., M.S.
Vice Dean for Research (Interim), Professor and Chair,
UT Health Science Center, San Antonio
Elizabeth D. Buttermore, Ph.D.
Director of Translational In Vitro Models,
Rosamund Stone Zander Translational Neuroscience Center, Boston Children’s Hospital
Moses Chao, Ph.D.
Professor, Department of Neuroscience
and Physiology,
New York University
Merit Cudkowicz, M.D.
Chief, Neurology Department; Director, Sean M. Healey & AMG Center for ALS; Julieanne Dorn Professor of Neurology,
Harvard Medical School
Michela Deleidi, M.D., Ph.D.
Helmholtz Group Leader, DZNE German Center for Neurodegenerative Diseases,
University of Tübingen
Biljana Djukic, Ph.D.
Translational Medicine and Early Development Lead, Neurology and Rare Diseases,
Sanofi
Fanny Elahi, M.D., Ph.D.
Asst. Professor of Neurology & Neuroscience; Asst. Professor of Pathology, Molecular and Cell-Based Medicine,
Icahn School of Medicine at Mount Sinai
Lisa Ellerby, Ph.D.
Professor,
Buck Institute
Kenneth Fischbeck, M.D.
NIH Distinguished Investigator,
NIH NINDS
Brad Friedman, Ph.D.
Senior Principal Scientist, Department of OMNI Bioinformatics,
Genentech, Inc.
Judith Frydman, Ph.D.
Donald Kennedy Chair, School of Humanities and Sciences and Professor of Genetics,
Frydman Lab, Stanford University
Jonathan Glass, M.D.
Professor of Neurology & Pathology, Director of the Emory ALS Center,
Emory University
Orla Hardiman, M.D., FRCPI
Professor of Neurology/Head of Academic, Clinical Medicine,
Trinity College of Dublin
Erika Holzbaur, Ph.D.
Professor of Physiology,
University of Pennsylvania, Perelman School of Medicine
Aimee Kao, M.D., Ph.D.
John Douglas French Foundation Endowed Professor; Director, Medical Scientist Training Program,
Memory and Aging Center, University of California, San Francisco
Zaven Kaprielian, Ph.D.
Chief Scientific Officer,
Remix Therapeutics
Holly Kordasiewicz, Ph.D.
Vice President, Neurology Research,
Ionis Pharmaceuticals
Sarah Kucenas, Ph.D
Professor of Biology, Cell Biology, and Neuroscience,
University of Virginia
Jim Kupiec, M.D.
Chief Clinical Development Officer,
Cassava Sciences
Claire Le Pichon, Ph.D.
Principal Investigator,
NIH Unit on the Development of Neurodegeneration
Pamela Maher, Ph.D.
Research Professor, Cellular Neurobiology Laboratory,
Salk Institute
Robert Mays, Ph.D.
Executive Vice President of Regenerative Medicine & Head of Neuroscience Programs,
Athersys
Alexander McCampbell, Ph.D.
Global Head of Neuroscience & Rare Diseases Research,
Roche
Jere Meredith, Jr., Ph.D.
Senior Director Neuroscience,
Arvinas
Robert Miller, Ph.D.
Chair, Target ALS IRC
Vice Dean for Research & Academic Affairs, George Washington University
Kelly Monk, Ph.D
Co-Director,
Vollum Institute
Richard Olson, Ph.D.
Director, Small Molecule Drug Discovery,
Bristol Myers Squibb
Manuela Polydoro, Ph.D.
VP, Head of Translational Medicine,
Muna Therapeutics
Mahendra Rao, M.D., Ph.D.
Chief Executive Officer,
Implant Therapeutics
Rajiv Ratan, M.D., Ph.D.
Chief Executive Officer, Burke Institute, and Associate Dean,
Weill Medical College at Cornell University
Ian Reynolds, Ph.D.
President,
YaghPenn Consulting
Tracy Saxton, Ph.D.
Managing Director,
Saxton Biopharma Consulting, LLC
Rob Scannevin, Ph.D.
Chief Scientific Officer,
Verge Genomics
Eric Schaeffer, Ph.D.
Chief Scientific Officer,
Paros Bio
Kimberly Scearce-Levie, Ph.D.
Vice President, Translational Sciences,
Denali Therapeutics
Holly Soares, Ph.D.
Head of Precision Medicine, VP,
Pfizer
Ajay Verma, M.D., Ph.D.
Frank Walsh, Ph.D.
Founder and Chief Executive Officer,
Ossianix
Andrew Wood, Ph.D.
VP, Clinical Neuroimaging Research,
CHDI

Conflict of Interest Committee

The Target ALS Conflict of Interest Committee ensures that the Independent Review Committee has no stake in projects selected and addresses any conflict of interest issues raised by the research community.

The committee is chaired by Zach Hall, Ph.D., Former Director of National Institute of Neurological Disorders and Stroke.

Daniel L. Doctoroff
Founder & Board Chair, Target ALS
Founder & CEO, Sidewalk Labs
Zach Hall, Ph.D.
Chair, Target ALS COI Committee
Former Director, NIH NINDS
Robert Miller, Ph.D.
Chair, Target ALS IRC
Vice Dean for Research & Academic Affairs, George Washington University
Neil Shneider, M.D., Ph.D.
Director, Eleanor and Lou Gehrig ALS Center,
Columbia University
James Treanor, Ph.D.
Board Member and Former CEO,
ADRx

Footer

  • Challenge
  • Contact
  • Our Approach
  • Resources For Scientists
  • Donate
  • Call For Proposals
  • Funded Consortia
  • Annual Meeting
  • Privacy Policy
  • Credits

Follow Us

guidestar charity-navigator

The Target ALS (TALS) website is intended for informational purposes only. Opinions expressed may not be that of TALS or its employees. For more information about our digital policies, click here.

© 2023 Target ALS Foundation, Inc.
Target ALS Foundation
P.O. Box 1598
New York, NY 10101
(332) 333-4140
Steck Insights WordPress Consulting